Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that patients with alopecia areata taking ritlecitinib reported higher satisfaction with hair growth after 24 and 48 weeks compared to those taking a placebo, aligning with improvements in hair growth noted by doctors.

A new mutation in the TRPS1 gene caused Trichorhinophalangeal syndrome in a 17-year-old, highlighting the need for genetic testing.

This report details a case of severe recurrent bacterial vaginosis in a woman with Netherton's syndrome.

In this case report, a 17-year-old male with a specific TRPS1 gene mutation presented with sparse, soft hair, short thumbs and toes, misaligned teeth, and distinctive bone abnormalities in the fingers and toes as observed through X-ray analysis.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study found that Nardostachys jatamansi DC rhizome extracts and specific isolated terpenoids promoted hair growth.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study identified a mutation in the keratin 71 gene that causes curly hair in certain rats, advancing our understanding of hair formation.

The document is a list of authors for the 67th volume of a publication, but it cannot be processed.

A 7-year-old girl was diagnosed with Netherton's Syndrome, shown by skin and hair symptoms.

This article reports a case of Netherton's syndrome that responded to 12% ammonium lactate lotion, suggesting potential treatment benefits for skin and allergic symptoms in this rare condition.

In this study, patients with treatment-refractory alopecia areata who received oral ritlecitinib 50 mg daily experienced significant hair regrowth, with 52.6% achieving complete scalp regrowth and improved Severity of Alopecia Tool scores, indicating its potential effectiveness in real-world settings.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In this study, introducing the rat OTC gene into spf-ash mice led to increased OTC activity and normalized hair growth and biochemical markers like urinary orotic acid and serum citrulline, partially correcting the symptoms of OTC deficiency.

This study found that PRMT5 inhibitors showed potent anti-tumor activity in models of adenoid cystic carcinoma and that combining these inhibitors with lenvatinib may have additional growth-inhibitory effects.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

This article discusses the human KRT72 wild-type allele's role in hair formation and reports no new research findings.

This study found that the highest antioxidant-activity formulation of the RENTT herbal combination effectively stimulated hair growth in mice and may serve as a natural therapy for chemotherapy-induced alopecia.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

This study found that among Japanese IBD patients, the NUDT15 p.Arg139Cys variant was significantly associated with thiopurine-induced leukopenia and severe hair loss, suggesting its genotyping is important for predicting these adverse events.

This study identified a new pathogenic variant, c.1081G>T; p.(Glu361*), in the KRT31 gene as a cause of autosomal-dominant monilethrix, highlighting the role of hair keratin proteins in hair and nail tissue disorders.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study observed that proretinal nanoparticles delivered significantly higher concentrations of retinal to the stratum corneum and hair follicles compared to non-particulate forms, potentially improving topical retinoid therapy.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.